A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

NCT04270747 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

576

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Interventions

DRUG: ABP 938
DRUG: Aflibercept

Sponsor

Amgen

Collaborators

[object Object]